Symptoms and General Pathology

All Conditions

Nausea

Vomiting

Signs and Symptoms, Digestive

Antineoplastic Agents

All Drugs and Chemicals

Anti-Inflammatory Agents

Antiemetics

Gastrointestinal Agents

Dermatologic Agents

Central Nervous System Depressants

Psychotropic Drugs

Cardiotonic Agents

Paclitaxel

Carboplatin

Dexamethasone

Ondansetron

Fosaprepitant

Albumin-Bound Paclitaxel

Dexamethasone acetate

Olanzapine

Neurokinin-1 Receptor Antagonists

Prochlorperazine

Substance P

Neurokinin A

Glucocorticoids

Hormones

Hormone Antagonists

Antineoplastic Agents, Hormonal

Serotonin

Serotonin 5-HT3 Receptor Antagonists

Neurotransmitter Agents

Antipsychotic Agents

Selective Serotonin Reuptake Inhibitors

Dopamine

Dopamine Antagonists

Dopamine Agents

Nk1-RA will be given on day 1 of each 3-week chemotherapy cycle, for up to 6 cycles.

Olanzapine will be given on days 1-4 of each 3-week chemotherapy cycle, for up to 6 cycles.

8 mg IV or 16 mg by mouth on day 1 pre-chemotherapy; then 8 mg by mouth twice a day on days 2-4 of chemotherapy

Neurokinin-1 Receptor Antagonist (NK1-RA)

5 mg by mouth on days 1-4 of chemotherapy (taken at night)

5-10 mg by mouth, available as needed, every 6 hours, days 1-5

Compazine

Aimee Rolston

The objective of this study is to investigate the efficacy of olanzapine as compared to neurokinin-1 receptor antagonists (NK1-RAs) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic malignancies receiving single day outpatient chemotherapy (carboplatin and paclitaxel) every 3 weeks.

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

Phase III Randomized Control Trial Investigating Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Patients With Gynecologic Malignancies Receiving Every 3-week Carboplatin and Paclitaxel Chemotherapy

Complete response (CR) is defined as no episodes of vomiting and no use of rescue antiemetic medications. Patient reported diaries will be used to measure this outcome.

Patients will record daily levels of nausea after chemotherapy using a Likert scale ranging from 0-10 (0 indicating no nausea; 10 indicating maximum level of nausea).

Patients will record daily levels of nausea using a Likert scale ranging from 0-10 (0 indicating no nausea; 10 indicating maximum level of nausea).

Patients will record daily levels of undesired sedation using a Likert scale ranging from 0 to 10 (0 indicating no undesired sedation; 10 indicating maximum level of undesired sedation).

Patients will record daily levels of undesired increase in appetite using a Likert scale ranging from 0 to 10 (0 indicating no undesired increase in appetite; 10 indicating maximum level of undesired increase in appetite).

University of Michigan Rogel Cancer Center

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients	NCT04503668	Gynecologic Can...	Ondansetron Dexamethasone Neurokinin-1 Re... Olanzapine Compazine	18 Years - 89 Years	University of Michigan Rogel Cancer Center
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients	NCT04503668	Gynecologic Can...	Ondansetron Dexamethasone Neurokinin-1 Re... Olanzapine Compazine	18 Years - 89 Years	University of Michigan Rogel Cancer Center
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients	NCT04503668	Gynecologic Can...	Ondansetron Dexamethasone Neurokinin-1 Re... Olanzapine Compazine	18 Years - 89 Years	University of Michigan Rogel Cancer Center

Spots Global Cancer Trial Database for compazine

Every month we try and update this database with for compazine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for compazine

Every month we try and update this database with for compazine cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for compazine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.